Actively Recruiting

Age: 18Years - 75Years
MALE
NCT06529549

Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment

Led by Sun Yat-sen University · Updated on 2024-07-31

30

Participants Needed

1

Research Sites

179 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This observational study aims to learn about the effects and safety of organoid-based drug sensitivity screening in mCRPC patients with bone metastases that progressed after first-line treatment. The main question it seeks to answer is: Do doctors choose treatment agents based on organoid-based drug sensitivity screening results for mCRPC patients, resulting in a better response? Participants already took bone metastasis biopsies for genetic testing based on current clinical guidelines. This study only takes residual tissue from biopsies for organoid culture.

CONDITIONS

Official Title

Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment

Who Can Participate

Age: 18Years - 75Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing and able to provide informed consent
  • Adult males aged 18 to 75 years
  • History of confirmed adenocarcinoma by histology or cytology
  • Documented metastatic castration-resistant prostate cancer progressed after first-line treatment
  • Evidence of target lesion on imaging studies
  • ECOG performance status of 0 or 1
  • Estimated survival of at least 12 weeks
Not Eligible

You will not qualify if you...

  • Do not meet the inclusion criteria
  • Receiving other anti-tumor therapies such as chemotherapy or immunotherapy
  • Received organ transplantation within the last 3 months
  • Have autoimmune diseases or acute infection with HBV, HCV, or HIV
  • Have pneumonia
  • Have severe concurrent illness or co-morbid conditions making them unsuitable
  • Unwilling or unable to provide informed consent
  • Judged unsuitable for clinical trial participation by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China, 510060

Actively Recruiting

Loading map...

Research Team

Y

Yonghong Li, MD

CONTACT

D

Diwei Zhao

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment | DecenTrialz